About Ipsen
Ipsen is a dynamic global biopharmaceutical group focused on transformative medicines in oncology, rare disease, and neuroscience.
Headquarters
Paris, France
Milestones
Milestones as listed on ipsen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
1954
Laboratoires Beaufour launches betaine citrate
Early product used for symptomatic treatment of dyspepsia.
Source: ipsen.com
1965
L'Isle-sur-la-Sorgue factory and Plessis-Robinson research centre
Source: ipsen.com
1975
Ipsen subsidiary created
Laboratoires Beaufour created the Ipsen subsidiary and began internationalising.
Source: ipsen.com
1983
Fondation Ipsen created
Set up to encourage exchanges between life-science researchers.
Source: ipsen.com
Leadership Team
Leadership as listed on ipsen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Olivia Brown
Executive Vice President, Global Head of Neuroscience and Aesthetics
Source: ipsen.com
Josep Catllà
Executive Vice President, Chief Corporate Affairs Officer
Source: ipsen.com
Aymeric Le Chatelier
Executive Vice President, Chief Financial Officer
Source: ipsen.com
Products & Services
Products and services as listed on ipsen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
All
Rare disease
Oncology
Neuroscience
Rare disease Bylvay (odevixibat)
Rare disease medicine in Ipsen's portfolio.
Source: ipsen.com
Oncology Cabometyx (cabozantinib)
Oncology medicine based on cabozantinib.
Source: ipsen.com
Oncology Cometriq (cabozantinib)
Second cabozantinib-based oncology product.
Source: ipsen.com
Oncology Decapeptyl (triptorelin)
Triptorelin-based oncology medicine, first launched in 1986.
Source: ipsen.com
Neuroscience Dysport (abobotulinumtoxinA)
Botulinum toxin product in the neuroscience portfolio.
Source: ipsen.com
Sites in Ireland
Blanchardstown, Dublin
Manufacturing, R&D, commercial
Irish site since 1989 producing oncology APIs, with an API R&D team and commercial functions.
Source: ipsen.com
Sites as listed on ipsen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Pipeline & Regulatory Record
What public registers list for Ipsen: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.
33Trials as lead sponsor
15Recruiting now
0With a site in Ireland
0FDA device clearances
Clinical trials 33 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|
| Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) NCT07497724 · PFIC - Progressive Familial Intrahepatic Cholestasis |
Observational | Active, closed |
| A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours NCT07441707 · Low-grade Glioma |
Phase 1 | Active, closed |
| A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows NCT07427797 · Moderate to Severe Glabellar Lines |
Phase 3 | Active, closed |
| A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows NCT07435428 · Moderate to Severe Glabellar Lines |
Phase 3 | Active, closed |
| A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours NCT06833008 · Advanced Solid Tumor |
Phase 1/2 | Active, closed |
| A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) NCT06730061 · Primary Biliary Cholangitis |
Phase 3 | Active, closed |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment NCT06447168 · Primary Biliary Cholangitis |
Observational | Active, closed |
| A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults NCT06625060 · Episodic Migraine, Chronic Migraine |
Phase 2 | Active, closed |
| A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours NCT06305247 · Melanoma, Head and Neck Squamous Cell Carcinoma |
Phase 1/2 | Active, closed |
| CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity NCT06245772 · Upper Limb Injury |
Observational | Active, closed |
Showing 10 of 33, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Drugs in these trials 5 compounds
NICE technology appraisals 1 of its medicines · 1 current
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Group (Ipsen): founded 1929, website ipsen.com. Wikidata Q111546 · Wikipedia. From Wikidata (CC0), matched by the group's Legal Entity Identifier.
How this is matched: register records are linked to this page by the organisation name they carry, here Ipsen; IPSEN. Spot a wrong match? Tell us.
Financials & Irish Entities
Ipsen does not file annual reports with the US SEC, so we do not show its financial statements here.
Companies registered in Ireland 2 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|
| Ipsen Manufacturing Ireland Limited LTD - Private Company Limited by Shares | 140251 | 1989 | Dec 2024 |
| Ipsen Pharmaceuticals Limited LTD - Private Company Limited by Shares | 173934 | 1991 | Dec 2024 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Ipsen as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.
In the News
No coverage yet — our newsroom tracks Ipsen continuously.
Research Publications
EUROPE PMC · LIVE
Searching Europe PMC for affiliated publications...
FDA Recalls (US)
OPENFDA · LIVE
Checking openFDA drug-recall records...
